Cite
HARVARD Citation
Luo, Y. et al. (2018). Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models. International journal of cancer. 142 (10), pp. 2163-2174. [Online].